Marina Biotech's approach to the development of RNAi-based therapeutics is founded on the natural precision of siRNA and shRNA's ability specifically target and subsequently down-regulate the over-expression of disease-causing proteins. Our scientific expertise and discovery approach allows us to create optimal drug candidates that achieve high potency with lower risk of immunological response and reduced off-target activity through our tauRNAi and tkRNAi drug discovery platforms.
